Copeland surface replacement of the shoulder. Results of an hydroxyapatite-coated cementless implant in patients over 80 years of age.
We describe the results of Copeland surface replacement shoulder arthroplasty using the mark III prosthesis in patients over 80 years of age. End-stage arthritis of the shoulder is a source of significant pain and debilitating functional loss in the elderly. An arthroplasty offers good relief of pain and may allow the patient to maintain independence. The risk-benefit ratio of shoulder replacement may be felt to be too high in an elderly age group, but there is no published evidence to support this theory. We have assessed whether the procedure was as reliable and safe as previously seen in a younger cohort of patients. Between 1993 and 2003, 213 Copeland surface replacement arthroplasty procedures were performed in our unit, of which 29 (13.6%) were undertaken in patients over the age of 80. This group of patients was followed up for a mean of 4.5 years (2.1 to 9.3). Their mean age was 84.3 years (81 to 93), the mean operating time was 40 minutes (30 to 45) and the mean in-patient stay was five days (2 to 21). There were no peri-operative deaths or significant complications. The mean Constant score adjusted for age and gender, improved from 15.1% to 77%. Copeland surface replacement shoulder arthroplasty may be performed with minimal morbidity and rapid rehabilitation in the elderly.
Mullett
H
H
Reading Shoulder Surgery Unit, Royal Berkshire Hospital, London Road, Reading RG1, 5AN, UK.
Levy
O
O
Raj
D
D
Even
T
T
Abraham
R
R
Copeland
S A
SA
D000369:Aged, 80 and over; D019643:Arthroplasty, Replacement / Q000379:methods* / Q000534:rehabilitation; D001672:Biocompatible Materials; D017886:Durapatite; D005260:Female; D006801:Humans; D007595:Joint Prosthesis; D008297:Male; D017060:Patient Satisfaction; D011474:Prosthesis Design; D016059:Range of Motion, Articular; D012785:Shoulder Joint / Q000601:surgery*; D016896:Treatment Outcome
D001672:Biocompatible Materials; D017886:Durapatite